100 studies found for:    coronado
Show Display Options
Rank Status Study
1 Withdrawn TSO for Plaque Psoriasis
Condition: Plaque Psoriasis
Intervention: Biological: Trichuris Suis Ova
2 Completed Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD treatment;   Other: Standard of care (Control)
3 Unknown  Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova (TSO);   Biological: Placebo
4 Active, not recruiting Trichuris Suis Ova in Autism Spectrum Disorders
Condition: Autism
Intervention: Drug: Trichuris Suis Ova
5 Terminated
Has Results
Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis
Condition: Nonalcoholic Steatohapatitis
Interventions: Drug: Roflumilast;   Drug: Pioglitazone;   Drug: Placebo
6 Terminated Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
Condition: Autism
Interventions: Biological: Trichuris suis ova;   Other: Placebo
7 Recruiting CNDO-109-AANK for AML in First Complete Remission (CR1)
Condition: Acute Myeloid Leukemia
Intervention: Biological: CNDO-109-AANK Cells
8 Completed
Has Results
Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova;   Other: Placebo
9 Recruiting Lumbar Stabilization Exercises vs Flexor Exercises in Degenerative Spondylolisthesis
Conditions: Degenerative Spondylolisthesis;   Chronic Low Back Pain
Interventions: Other: Lumbar stabilization exercises;   Other: Flexor exercises
10 Recruiting Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: liraglutide;   Drug: alpha-glucosidase inhibitors;   Drug: DPP-4 inhibitors;   Drug: meglitinides;   Drug: SGLT-2 inhibitors;   Drug: sulfonylurea;   Drug: thiazolidinediones
11 Recruiting Efficacy and Safety of MK-3682B (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
Conditions: Hepatitis;   Hepatitis C;   Digestive System Diseases;   Flaviviridae Infections;   Hepatitis, Viral, Human;   Liver Diseases;   RNA Virus Infections;   Virus Diseases
Interventions: Drug: MK- 3682B;   Drug: Ribavirin
12 Recruiting Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: semaglutide;   Drug: sitagliptin;   Drug: placebo
13 Active, not recruiting A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
Conditions: Hepatitis C Viral Infection;   Chronic Hepatitis C;   Hepatitis C (HCV);   Hepatitis C Genotype 4
Interventions: Drug: Faldaprevir;   Drug: TD-6450;   Drug: Ribavirin
14 Active, not recruiting Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: semaglutide;   Drug: liraglutide;   Drug: placebo
15 Enrolling by invitation A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
Condition: Hepatitis C
Interventions: Drug: ABT-493;   Drug: ABT-530
16 Recruiting Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
Conditions: Chronic Liver Disease;   Thrombocytopenia
Interventions: Drug: Lusutrombopag;   Drug: Placebo
17 Recruiting Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Condition: Hepatitis C
Interventions: Drug: Grazoprevir;   Drug: MK-3682;   Drug: MK-8742;   Drug: MK-8408;   Drug: MK-3682B;   Drug: RBV
18 Recruiting Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
Conditions: Hepatitis C;   Cirrhosis
Interventions: Drug: daclatasvir;   Drug: Sofosbuvir;   Drug: Ribavirin
19 Enrolling by invitation A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
Condition: Hepatitis C Virus Infection
Intervention: Drug: Sofosbuvir
20 Active, not recruiting A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
Condition: Hepatitis C Virus
Interventions: Drug: ombitasvir/ABT-450/ritonavir;   Drug: Ribavirin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years